




The relative strengths and weaknesses of Briacell Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Briacell Therapeutics Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Briacell Therapeutics Corp is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 9.9% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	19,927
Cost of Goods Sold	0
Intangible Assets	185
Liabilities, Current	3,978
Liabilities, Non-Current	338
Other Assets	1,242
Other Compr. Net Income	0
Other Expenses	-758
Other Liabilities	0
Other Net Income	-110
Other Revenues	0
Property and Equipment	297
Research and Development	21,271
Selling, General and Administrative Expense	5,934

Output Variable	Value in 1000 USD
Assets	21,650
Liabilities	4,316
Expenses	26,446
Revenues	0
Stockholders Equity	17,334
Net Income	-26,556
Comprehensive Net Income	-26,556
BaseVar	26,261
ECR before LimitedLiability	87%
Economic Capital Ratio	219%